Last reviewed · How we verify
6-month dual anti-platelet therapy — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
6-month dual anti-platelet therapy (6-month dual anti-platelet therapy) — Gangnam Severance Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 6-month dual anti-platelet therapy TARGET | 6-month dual anti-platelet therapy | Gangnam Severance Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 6-month dual anti-platelet therapy CI watch — RSS
- 6-month dual anti-platelet therapy CI watch — Atom
- 6-month dual anti-platelet therapy CI watch — JSON
- 6-month dual anti-platelet therapy alone — RSS
Cite this brief
Drug Landscape (2026). 6-month dual anti-platelet therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/6-month-dual-anti-platelet-therapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab